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Abstract
LRRK2, a Parkinson’s disease associated gene, is highly expressed in microglia in addition to neurons; however, its function
in microglia has not been evaluated. Using Lrrk2 knockdown (Lrrk2-KD) murine microglia prepared by lentiviral-mediated
transfer of Lrrk2-specific small inhibitory hairpin RNA (shRNA), we found that Lrrk2 deficiency attenuated lipopolysaccharide
(LPS)-induced mRNA and/or protein expression of inducible nitric oxide synthase, TNF-a, IL-1b and IL-6. LPS-induced
phosphorylation of p38 mitogen-activated protein kinase and stimulation of NF-kB-responsive luciferase reporter activity
was also decreased in Lrrk2-KD cells. Interestingly, the decrease in NF-kB transcriptional activity measured by luciferase
assays appeared to reflect increased binding of the inhibitory NF-kB homodimer, p50/p50, to DNA. In LPS-responsive
HEK293T cells, overexpression of the human LRRK2 pathologic, kinase-active mutant G2019S increased basal and LPS-
induced levels of phosphorylated p38 and JNK, whereas wild-type and other pathologic (R1441C and G2385R) or artificial
kinase-dead (D1994A) LRRK2 mutants either enhanced or did not change basal and LPS-induced p38 and JNK
phosphorylation levels. However, wild-type LRRK2 and all LRRK2 mutant variants equally enhanced NF-kB transcriptional
activity. Taken together, these results suggest that LRRK2 is a positive regulator of inflammation in murine microglia, and
LRRK2 mutations may alter the microenvironment of the brain to favor neuroinflammation.
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Introduction
Parkinson’s disease (PD), the second-most common neurode-
generative disorder, is caused by degeneration of dopaminergic
neurons in the substantia nigra (SN). Leucine-rich repeat kinase 2
(LRRK2), an autosomal dominant gene in familial PD, consists of
six functional domains: ankyrin-like (ANK), leucine-rich repeat
(LRR), Ras of complex (ROC), C-terminal of ROC (COR),
kinase, and WD40 domains. To date, 51 disease-associated
mutations in LRRK2 have been identified in familial or sporadic
cases. These mutations are scattered throughout the entire
LRRK2 gene, and include R1441C/G/H in the ROC domain,
G2019S in the kinase domain, and G2385R in the WD40 domain
[1–4]. Although there is evidence showing that expression of
pathological LRRK2 mutations is sufficient to cause neurotoxicity
in vitro [5,6], transgenic LRRK2 mutant mice show little or no
obvious degeneration of dopaminergic neurons [7–10]. Therefore,
it has been suggested that certain changes in the brain
microenvironment may cooperate with genetic defects to promote
the development of PD [11].
Although the etiology of PD is poorly understood, it is generally
accepted that inflammatory processes are a risk factor [12,13]. It
has been reported that activated microglia expressing a large
number of inflammatory genes are elevated in the striatum and
SN region of PD patients and in animal models of PD, and
mediate dopaminergic neuronal death [12,14,15]. Immune cells,
such as B lymphocytes, lymphoblasts, monocytes, and microglia,
express high levels of LRRK2, suggesting a role in immune
responses [16–18]. Blood mononuclear cells from patents bearing
an LRRK2-G2019S mutation exhibits large differences in
transcriptional profiles of immune-response genes compared to
healthy control cells [19]. Moreover, genome-wide association
studies have identified single-nucleotide polymorphisms (SNPs) of
LRRK2 in a susceptibility locus for chronic inflammatory diseases
such as Crohn’s disease and leprosy [20,21]. However, few details
about the roles of LRRK2 in immune response are known.
In this study, we demonstrate that LRRK2 acts through
regulation of p38 MAPK and NF-kB signaling pathways to
stimulate microglial inflammatory responses. These results suggest
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34693that LRRK2 mutations could change the microenvironment of
brain, and thereby trigger and/or enhance the pathogenesis of
PD.
Methods
Reagents
DMEM and FBS were from Hyclone (Logan, UT, USA). AMV
reverse transcriptase was from Genedepot (Barker, TX, USA).
PCR primers and biotin-labeled DNA probe were obtained from
IDT (Coralville, IA, USA). The expression vectors pCDNA3-
hCD14, pFlag-CMV1-hMD2, and pCDNA3-hTLR4-YFP were
obtained from Addgene (Cambridge, MA, USA). 36myc-tagged
human LRRK2-WT, LRRK2-R1441C, LRRK2-D1994A, and
LRRK2-G2019S expression plasmids were prepared by cloning
into pcDNA3.1 as described previously [22,23]. Antibodies to
mouse inducible nitric oxide synthase (iNOS) were purchased from
Millipore (Temecula, CA, USA); antibodies to mouse Lrrk2,
human LRRK2 (hLRRK2), phosphorylated (p)-p38 (Thr180/
Tyr182), p-JNK (Thr183/Tyr185), p-ERK (Thr202/Tyr204), and
p-MKK3/6 (Ser189/207) were from Cell Signaling Technology
(Danvers, MA, USA). Antibodies to Myc were from Sigma (St.
Louis, MO, USA); antibodies to a-tubulin, p38, MKK3/6, NF-kB
p65, and NF-kB p105/p50 were from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Lipoteichoic acid (LTA), CL097, and
ODN 1668, were obtained from Invivogen (San Diego, CA, USA).
Polybrene, puromycin, and other unspecified reagents were from
Sigma.
BV-2 microglia culture and construction of Lrrk2-
knockdown microglia
BV-2, immortalized murine microglial cell line, were obtained
from Dr. E.J. Choi (Korea University, Korea) and cultured as
described previously [24]. BV-2 cells were originally generated by
infecting primary microglia with a v-raf/v-myc recombinant
retrovirus, and retained most of the properties of freshly isolated
microglia [25]. Cells were subcultured at 70–80% confluence
almost daily. For construction of Lrrk2-knockdown (Lrrk2-KD)
microglia, cells were infected with lentiviral particles carrying three
small inhibitory hairpin RNAs (shRNAs) specific for mouse Lrrk2
(shLrrk2, sc-45750-V, Santa Cruz Biotechnology). Lentiviral
particles with non-targeted shRNAs (shNT, sc-108080, Santa
Cruz Biotechnology) were used as a negative control. Cells (5610
4
cells/mL) were seeded in 12-well plates and incubated with fresh
media containing polybrene (5 mg/mL) and lentiviral particles
(1.0610
5 IFU) for 12 h. Infected cells were selected with
puromycin (5 mg/mL for 2 d) and plated into 96-well plates at a
density of 0.5 cells/well for cloning. After clonal selection with
puromycin, seven Lrrk2-KD clones that expressed less than 20%
of basal levels of Lrrk2 mRNA and four control clones that
expressed normal levels of Lrrk2 mRNA were obtained.
Quantitative real-time reverse transcription-polymerase
chain reaction
Total RNA was isolated from microglia or whole bodies of flies
using easy-BLUE reagent (iNtRON Biotechnology, Seoul, Korea).
cDNA was prepared from total RNA using M-MLV reverse
transcriptase and oligo d(T)15 primers, according to the manufac-
turer’s instructions (Elpis Bio, Daejeon, Korea). cDNA and
forward/reverse primers (200 nM) were mixed with KAPA SYBR
Fast Master Mix (Cape Town, South Africa), and quantitative
real-time reverse transcription-polymerase chain reaction (qRT-
PCR) was carried out using an RG-6000 real-time amplification
instrument (Corbett Research, Sydney, Australia) under the
following conditions: denaturation at 95uC for 30 s, followed by
40 cycles of 95uC for 3 s and 60uC for 30 s. Threshold cycle (CT)
values were calculated for each gene, and normalized to that of
glyceraldehyde 3-phosphate dehydrogenase (Gapdh), used as an
internal reference. Expression levels relative to controls, expressed
as fold induction, were determined using the comparative CT
(2
2DDCT) method [26]. Details of primer sequences, product sizes,
and melting temperatures (Tm) are listed in Table 1. hLRRK2 was
also analyzed by conventional RT-PCR.
Western blot analysis
Cells were washed with PBS and lysed in modified RIPA buffer
(10 mM Na2HPO4 pH 7.2, 150 mM NaCl, 1% Nonidet P-40
[NP-40], 0.5% Na-deoxycholate) containing protease inhibitors
(2 mM PMSF, 10 mg/mL leupeptin, 10 mg/mL pepstatin, 2 mM
EDTA). Total proteins (50–100 mg) were separated by SDS-
PAGE, and transferred to nitrocellulose membranes. Membranes
were incubated with primary antibodies, followed by incubation
with horseradish peroxidase-conjugated secondary antibodies.
Protein bands were visualized using an enhanced chemilumines-
cence system.
ELISA
Culture media were collected, and the levels of mouse TNF-a
and IL-6 were measured using an ELISA kit (Invitrogen, Carlsbad,
CA, USA) according to instructions provided by Invitrogen.
Measurement of nitric oxide
The amount of nitrite formed from nitric oxide (NO) was
measured by mixing culture medium (50 mL) with an equal
volume of Griess reagent (0.1% naphthylethylene diamine, 1%
sulfanilamide, 2.5% H3PO4), and then measuring optical density
at 540 nm [27].
EMSA and supershift assays
NF-kB DNA-binding activity was measured using an EMSA, as
described previously. BV-2 or TCM-HEK cells (3610
6 cells) were
harvested and suspended in 900 mL hypotonic solution (10 mM
HEPES pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA,
1 mM DTT, 0.5 mM PMSF) for 15 min, followed by incubation
in hypotonic solution containing 0.5% (v/v) NP-40 for 5 min.
Cells were then centrifuged at 5006g for 10 min at 4uC, and the
pellet containing the nuclear fraction was resuspended in a
solution containing 20 mM HEPES (pH 7.9), 20% (v/v) glycerol,
0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, and
1 mM PMSF. Samples were centrifuged at 10,0006g for 10 min,
and supernatants (crude nuclear fractions) were collected and
stored at 270uC until use.
Oligonucleotides for the NF-kB consensus binding sequence, 59-
AGT TGA GGG GAC TTT CCC AGG C-39 (Santa Cruz
Biotechnology), were end-labeled using T4 polynucleotide kinase
(Promega, Madison, WI, USA) and [c-
32P] ATP (Perkin Elmer,
Waltham, MA, USA). The labeled DNA probe (0.5 ng) was
incubated for 30 min with 5 mg nuclear proteins in a reaction
mixture containing 21.4 mM EDTA, 21.4 mM EGTA, 20% (v/v)
glycerol, 0.29 mM ZnSO4, 10 ng/mL poly(dI-dC), 1 mM DTT,
0.4 mg/mL bovine serum albumin, and 8 mM MgCl2. For
supershift assays, nuclear extracts were preincubated with 1 mg
of a combination of anti-p65 and anti-p105/p50 antibodies for
10 min at 4uC before adding probe. Reaction mixtures were
resolved by electrophoresis on 6% (w/v) polyacrylamide gels.
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DNA affinity precipitation assays were performed as described
previously, with minor modifications [28]. Briefly, 100 mgo f
nuclear protein extracts prepared as described for EMSAs was
incubated with 59-biotinylated DNA probe (25 nM) containing the
NF-kB consensus motif, 59-AGT TGA GGG GAC TTT CCC
AGG C-39,a t4 uC for 1 h in DNA-binding buffer (20 mM Tris-Cl
pH7.4, 1 mM EDTA, 0.1% Triton X-100, 1 mg poly(dI-dC),
1 mM DTT, 4% glycerol). The NF-kB probe–protein complexes
were immobilized by incubating with streptavidin agarose resin
(Invitrogen) at 4uC for 30 min with gentle rotation, centrifuged,
and washed repeatedly with binding buffer. Collected protein
complexes were separated by SDS-PAGE, and the NF-kB
subunits bound to DNA probes were detected by immunoblotting
with p65 and p50 antibodies. The levels of nuclear translocated
NF-kB subunits were detected by resolving 10 mg of nuclear
protein that had not been reacted with probe on SDS-PAGE gels,
and then probing with antibodies against p65, p50, and TATA-
binding protein (TBP, nuclear internal control) by Western
blotting, as described above.
Plasmid constructs
LRRK2-G2385R, a pathogenic hLRRK2 mutant containing a
substitution in the WD domain, was constructed by site-direct
mutagenesis. Briefly, a 3.8-kb XbaI fragment from a pcDNA3.1
construct containing the C-terminus of LRRK2-WT was sub-
cloned into pSP72 (Promega). The LRRK2-G2385R mutation
was introduced into the pSP72-hLRRK2-WT plasmid using a
Quick Change site-directed mutagenesis kit (Stratagene, La Jolla,
CA, USA) and the primers pG2385R-F (59-ACT GAA AAA CTC
TGT AGA CTA ATA GAC TGC GTG-39) and pG2385R-R (59-
CAC GCA GTC TAT TAG TCT ACA GAG TTT TTC AGT-
39). The XbaI fragment from pSP72-LRRK2-G2385R was re-
introduced into the XbaI-digested pcDNA3.1-hLRRK2-WT
vector. The integrity and direction of the constructed clone were
confirmed by sequencing.
Luciferase reporter assay
BV-2 cells (6610
5 cells) plated in a 35-mm dish were transfected
with 1.2 mgo fa5 6 NF-kB-luciferase reporter construct
(Stratagene) and 0.3 mg CMV-b-gal (for normalization of
transfection efficiency) using 3 mL of JetPEI (Polyplus Transfec-
tion, Illkirch, France). After 24 h, cells were treated with 100 ng/
mL LPS for 3 h. Cells were lysed in passive lysis buffer (Promega).
Firefly luciferase (Luciferase Assay System) and b-galactosidase
(Beta-GLO Assay System) activities were measured according to
the manufacturer’s instructions (Promega).
Human embryonic kidney (HEK293T) cells were gifted from
Dr. H. Suh-Kim (Ajou University, Korea) and maintained in high-
glucose DMEM containing 10% FBS, 4 mM L-glutamine, and
1% penicillin/streptomycin. Cells were allowed to grow to
approximately 80–90% confluence before sub-culturing.
HEK293T cells were made LPS-responsive by seeding onto 24-
well plates at a density of 1610
5 cells/well, and then co-
transfecting with pCDNA3-hCD14, pFlag-CMV1-hMD2, and
pCDNA3-hTLR4-YFP (50 ng each). For experiments, LPS-
responsive HEK293T cells were co-transfected with the NF-kB-
luciferase reporter (100 ng/well), pRL-Tk (5 ng/well), and
250 ng/well LRRK2 expression vector or empty pcDNA3 (mock)
using 1 mL of JetPEI. After transfecting for 4 h, cells were washed
with fresh culture medium, maintained for 20 h, and then treated
with LPS for 6 h. Cells were lysed, and luciferase activity was
measured using the Dual-Luciferase Assay System (Promega).
Statistical analysis
Data were analyzed by Student’s t-test or one-way ANOVA
followed by post-hoc comparisons (Student-Newman-Keuls ap-
proach), using the Statistical Package for Social Sciences version
8.0 (SPSS Inc., Chicago, IL).
Results
Lrrk2 knockdown attenuates LPS-induced inflammatory
responses in microglia
As a first step in examining the role of Lrrk2 in microglia, we
developed stable murine Lrrk2 knockdown (Lrrk2-KD) microglia.
For this, we infected BV-2 microglia with lentiviral particles
encoding shRNAs targeting Lrrk2 or a non-targeting control
shRNA. We chose two Lrrk2-KD clones and two control clones
for these experiments. Lrrk2 mRNA and proteins levels were
dramatically reduced in Lrrk2-KD microglia (Fig. 1A). We then
analyzed the expression of the proinflammatory mediators TNF-a,
Table 1. List of primer sequences used for qRT-PCR.
1
Species Gene GeneBank ID Size (bp) Sequence (59-39)
Mouse GAPDH NM_008084.2 142 Fwd- GCCTTCCGTGTTCCTACC
Rev- CCTCAGTGTAGCCCAAGATG
LRRK2 NM_025730.3 145 Fwd- GCCACGAATCTCAATAGCAAG
Rev- CCAAAGCCAAGCACAGTATTC
iNOS NM_010927.3 150 Fwd- GCAAACATCACATTCAGATCCC
Rev- TCAGCCTCATGGTAAACACG
TNF-a NM_013693.2 134 Fwd- CTTCTGTCTACTGAACTTCGGG
Rev- CAGGCTTGTCACTCGAATTTTG
IL-1b NM_008361.3 148 Fwd- TCCTGTGTAATGAAAGACGGC
Rev- ACTCCACTTTGCTCTTGACTTC
IL-6 NM_031168.1 614 Fwd- CAAGAGACTTCCATCCAGTTGC
Rev- TTGCCGAGTAGATCTCAAAGTGAC
1Fwd, Forward primer; Rev, Reverse primer.
doi:10.1371/journal.pone.0034693.t001
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TNF-a and IL-6 secretion was significantly decreased at 3 and
24 hours compared to untransfected parental (2) cells and control
clones (Fig. 1B). iNOS protein expression and NO production
(detected as NO-derived nitrite by 48 hours after activation) were
also significantly reduced in Lrrk2-KD clones at 24 and 48 hours
(Fig. 1C, 1D). Consistent with the results, a qRT-PCR analysis
showed that LPS (100 ng/mL)-induced expression of IL-1b, IL-6,
and iNOS mRNA was dramatically reduced in Lrrk2-KD clones
at 3 and 9 hours (Fig. 1E). A significant decrease in TNF-a mRNA
expression was only detected at 3 hours since its expression
reduced to the basal level at 9 hours (Fig. 1E). We further
examined whether Lrrk2 affects other TLR receptors that have
potentials to induce inflammatory response in BV-2 microglia
[29]. Using agonists for TLR2 (lipoteichoic acid, LTA, 10 mg/ml),
TLR-7/8 (CL097, 500 ng/ml), and TLR-9 (ODN1668, 500 ng/
ml), we found that Lrrk2-KD could regulate inflammatory
responses mediated by these TLRs since nitric oxide production
induced by these TLR agonists were significantly reduced in Lrrk2
KD clones (Fig. 1F–H). Similar results were obtained in Drosophila
LRRK (dLRRK) loss-of-function mutant, LRRK
P1 [30]: mRNA
expression of antimicrobial proteins, attacin A and diptericin, was
significantly reduced in LRRK
P1 compared to wild type Drosophila
at 5-, or 30-days (Figure S1). Taken together, these results indicate
that LRRK2 is a positive regulator of inflammation.
Lrrk2 knockdown specifically attenuates LPS-induced
activation of p38 MAPK, but not JNK or ERK
MAPKs are critical signaling molecules in LPS-induced
microglial inflammatory processes [31]. Therefore, we examined
whether activation of MAPKs was impaired in Lrrk2-KD
microglia by analyzing phosphorylation of p38, JNK, and ERK
following LPS stimulation. Parental cells and control cells showed
similar levels of phosphorylated MAPKs (Fig. 2A, 2B). Interest-
ingly, the levels of phosphorylated p38 (p-p38) were specifically
attenuated in Lrrk2-KD cells between 15 and 60 min after LPS
treatment compared to that in parental and control cells while the
levels of p-ERK and p-JNK were not different (Fig. 2A, 2B). The
other Lrrk2-KD clone also showed attenuated p-p38 levels in
response to LPS (data not shown). Next, we analyzed activation of
MKK3/6, an upstream kinase of p38 MAPK. In response to LPS,
phosphorylation levels of serine 189/207 of MKK3/6 (p-MKK3/
6) increased from 15 to 60 min (Fig. 2C). However, p-MKK3/6
levels were not significantly different in parental, control, and
Lrrk2-KD cells (Fig. 2D, 2E).
Lrrk2 knockdown attenuates LPS-induced activation of
NF-kB and increases the DNA-binding activity of the NF-
kB p50 subunit
The transcription factor NF-kB is important in mediating the
expression of inflammatory genes in microglia [32–34]. To assess
the function of Lrrk2 in the process of inflammatory activation, we
analyzed the transcriptional activity of NF-kB in Lrrk2-KD
microglia by measuring the activity of a luciferase reporter
expressed under the control of a promoter containing five repeats
of an NF-kB-binding sequence. LPS (100 ng/mL) increased
luciferase activity by 3–4 fold in parental (2) and control cells;
in contrast, luciferase activity was increased only 1–2 folds in both
of Lrrk2-KD clones (Fig. 3A).
We next analyzed the molecular mechanism responsible for
Lrrk2-stimulated NF-kB transcriptional activity. Interestingly,
degradation of IkB protein, a prerequisite event for nuclear
translocation of NF-kB, was not different in control and Lrrk2-KD
cells; in cells of both clonal types, IkB protein was decreased at
approximately 30 min, but rebounded 60 min after LPS activa-
tion (Fig. 3B). This result suggests that diminished NF-kB
transcriptional activity in Lrrk2-KD cells is mediated by disruption
of a molecular mechanism downstream of IkB degradation.
A further investigation of the mechanism of Lrrk2 regulation of
NF-kB activity using EMSA analyses unexpectedly showed that
both lower (Fig. 4A, arrow) and upper (Fig. 4A, arrowhead) NF-
kB-DNA complexes, identified in supershift assays as p50/p50
homodimers and mainly p50/p65 heterodimers, respectively
(Fig. 4B), were somewhat more strongly detected in Lrrk2-KD
cells than in control cells between 15 and 60 min after LPS
stimulation. It has been reported that, unlike p50/p65 heterodi-
mers, p50/p50 homodimers function to inhibit transcription [35].
Thus, we analyzed nuclear proteins that bound to the NF-kB
binding DNA consensus sequence. For this, we incubated nuclear
extracts with a 59-biotinylated DNA probe and then precipitated
with streptavidin-agarose resin. Within 30 min, LPS induced the
nuclear translocation of p50 and p65 NF-kB subunits to a
comparable degree in both Lrrk2-KD and control cells (Fig. 4C,
Nuclear extract). Importantly, however, more p50 bound to DNA
in Lrrk2-KD cells; p65 binding was not different in these two types
of cells (Fig. 4C, DNA-binding). These results suggest that NF-kB
transcriptional activity is reduced in Lrrk2-KD cells because the
affinity of the inhibitory p50 subunit for the NF-kB consensus
sequence is higher in these cells than in controls.
Effect of overexpression of LRRK2-WT and LRRK2 mutants
on LPS-induced inflammatory responses
We next examined the effect of overexpression of hLRRK2 on
LPS-induced activation of MAPKs and NF-kB using HEK293T
cells. These cells were used because of low transfection efficiency of
BV-2 microglia. Because parental HEK293T cells do not respond
to LPS treatment [36], we transiently transfected HEK293T cells
with expression plasmids for the LPS receptor, TLR4, and
proteins of the downstream signaling machinery, CD14 and MD2
[37,38]. In these LPS-responsive TCM-HEK cells, LPS induced
phosphorylation of p38 and JNK within 60 min (Fig. 5A). Thus,
we analyzed the effect of LRRK2-WT and LRRK2 mutants on
basal and LPS-induced p38 and JNK phosphorylation levels in
TCM-HEK cells cotransfected with LRRK2-expression vectors or
empty vector (mock). Overexpression of LRRK2-WT and all
LRRK2 mutants, including kinase-active (G2019S), kinase-dead
(D1994A), and WD-domain (G2385R) mutants, tended to increase
basal levels of phosphorylated p38 compared to empty vector-
transfected (mock) cells, although the extent of the increase varied
depending on the specific LRRK2 variant. Basal levels of
phosphorylated JNK were also increased by overexpression of
LRRK2-WT and LRRK2-G2019S, but not by overexpression of
LRRK2-D1994A or LRRK2-G2385R (Fig. 5B, 5C). LPS
increased p38 and JNK phosphorylation in cells transfected with
LRRK2-WT, LRRK2-G2019S, and in mock-transfected cells, but
not in cells transfected with LRRK2-D1994A or LRRK2-G2385R
(Fig. 5B, 5C). Notably, LPS-induced p38 phosphorylation was
significantly increased in LRRK2-G2019S-expressing cells, and
LPS-induced JNK phosphorylation was increased in LRRK2-WT
and LRRK2-G2019S-expressing cells above the levels in mock
cells (Fig. 5B, 5C). The kinase-active mutant G2019S, in
particular, enhanced both basal and LPS-induced levels of
phosphorylated (activated) p38 and JNK, whereas the effects of
other LRRK2 mutants on p38 and JNK activation were variable.
However, as in microglia, overexpression of LRRK2-WT,
-G2019S, and -D1994A had no effects on p-MKK3/6 levels in
TCM-HEK cells in the absence and presence of LPS (Fig. 5D).
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LRRK2 mutants modified NF-kB transcriptional activity. Expres-
sion of LRRK2-WT increased NF-kB transcriptional activity in
HEK cells (left panel in Fig. 6A) as previously reported [16].
However, expression of TCM alone significantly enhanced NF-kB
transcriptional activity in HEK cells (Fig. 6A), and co-expression of
LRRK2-WT did not further increase NF-kB transcriptional
activity (left panel in Fig. 6A). Expression of LRRK2 was
confirmed with Western blot (right panel in Fig. 6A). Next, we
evaluated the effect of overexpression of LRRK2-WT on LPS-
induced NF-kB transcriptional activity in TCM-HEK cells:
LRRK2-WT compared to empty vector enhanced LPS-induced
NF-kB activity (Fig. 6B). This increase in NF-kB activity was LPS-
dose dependent in the range of 0.01–100 ng/mL, with maximum
activity obtained with 1 ng/mL LPS (Fig. 6B). We further
analyzed the effect of other LRRK2 mutants on NF-kB activity.
Interestingly, all LRRK2 mutants (R1441C, G2019S, G2385R,
and D1994A) significantly increased NF-kB activity, indicating
that the increase was independent of mutations in ROC, kinase,
and WD domains (Fig. 6C). In addition, G2019S showed dose-
response at 100 and 250 ng, but not at 750 ng (Fig. 6D). G2385R
also similarly increased NF-kB activity at 100 ng and 500 ng
Figure 1. Attenuation of inflammatory responses in Lrrk2-KD microglia. (A) BV-2 microglia were infected with lentivirus expressing non-
targeted (Con) or Lrrk2-targeted shRNA (KD). Two stable clones of each group were selected. Expression levels of Lrrk2 mRNA and protein were
analyzed by qRT-PCR (left) and Western blotting (right), respectively. Parental (2), con, and KD cells were treated with or without 100 ng/mL LPS (B–
E), 10 mg/mL LTA (F), 500 ng/mL CL097 (G), or 500 ng/ml ODN1668 (H) for indicated times (B, D, E), 12 h (C), 24 h (F), or 48 h (G, H). (B) TNF-a and IL-6
secretion into the culture medium were analyzed by ELISA. (C, D, F–H) iNOS protein expression was assayed by Western blotting (C), and NO release
was measured using the Griess reagent, as described in Materials and Methods (D, F–H). (E) TNF-a, IL-1b, IL-6 and iNOS mRNA levels were analyzed by
qRT-PCR. Gapdh mRNA and a-tubulin protein levels were analyzed as internal controls for qRT-PCR and Western blotting, respectively. Values are
means 6 SEMs (*p,0.05, **p,0.01 vs. control). Data are representative of at least three independent experiments unless indicated otherwise.
doi:10.1371/journal.pone.0034693.g001
Figure 2. LPS-induced p38 phosphorylation is specifically inhibited in Lrrk2-KD cells. (A, C, D) Cells were incubated with LPS (100 ng/mL)
for the indicated times (A, C) or 30 min (D), and the levels of phosphorylated p38 (p-p38), JNK (p-JNK), ERK (p-ERK), and total p38 (A) or total and
phosphorylated MKK3/6 (C, D) were determined by Western blotting. a-tubulin was used as an internal control. (B, E) Band intensities of p-p38 (B)
and p-MKK3/6 (D) were quantified using a densitometer. Values are means 6 SEMs of three independent experiments (*p,0.05, **, p,0.01 vs.
control). Data are representative of three independent experiments.
doi:10.1371/journal.pone.0034693.g002
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saturated at quite low Lrrk2 levels.
Next, we further analyzed the effect of LRRK2 overexpression on
the formation of NF-kB-DNA complexes in TCM-HEK cells since
the p50 binding to the NF-kB consensus sequence increased in
response to LPS in Lrrk2-KD microglia (Figs. 4 and 6E–F).
However, there was no significant difference in NF-kB-DNA
complex formation in LRRK2-overexpressing and vector-transfect-
ed(mock)cellsbetween30 minand2 hafterLPSactivation(Fig.6E,
arrowhead). Supershift assay with p50 and p65 antibodies showed
that the NF-kB-DNA complex is p50/p65 heterodimers, and no
p50/p50 homodimer was detected in TCM-HEK cells (Fig. 6F).
Taken together, the results of this study suggest that LRRK2
regulates inflammation in settings as diverse as murine microglia
and TCM-HEK cells. Furthermore, p38 and JNK MAPK, and
NF-kB signaling pathways are possible targets of LRRK2.
Discussion
Although PD is caused by the degeneration of dopaminergic
neurons in the SN, the cause of neuronal loss could reflect changes
Figure 3. NF-kB transcriptional activity, but not IkB degrada-
tion, is decreased in Lrrk2-KD cells. (A) Parental (2), control (Con)
and Lrrk2-KD (KD) cells were transfected with a 56 NF-kB-luciferase
reporter plasmid (pDNA), and luciferase activity was measured 3 h after
LPS stimulation. (B) Cells were treated with LPS for the indicated times,
and IkB levels were analyzed by Western blotting. Relative IkB levels
were quantified using a-tubulin as an internal control. Values in (A) and
(B) are means 6 SEMs of three independent experiments (*p,0.05).
doi:10.1371/journal.pone.0034693.g003
Figure 4. The DNA-binding ability of p50 is increased in Lrrk2-
KD microglia in response to LPS stimulation. (A) The DNA-
binding activity of NF-kB was analyzed by EMSA. Nuclear extracts were
prepared from control and Lrrk2-KD cells at the indicated times after
LPS treatment. Specific binding was analyzed using an excess (206)o f
unlabeled (Cold) consensus NF-kB sequence. Two specific NF-kB-DNA
complex bands (arrowhead and arrow) were detected. (B) A supershift
assays were performed using NF-kB p50 and p65 antibodies. Nuclear
extracts obtained 30 min after LPS treatment were preincubated with
antibodies. Arrows and arrowheads in (A, B) indicate p50/p50 complex
and p50/p65 complex, respectively. (C) DNA affinity precipitation assays
were performed using nuclear extracts prepared from untreated and
LPS-treated control and Lrrk2-KD microglia. Nuclear extracts (100 mg
protein) were incubated with biotin-labeled NF-kB consensus sequence,
and then precipitated with streptavidin-conjugated agarose beads. The
amount of p50 or p65 in the nuclear extracts (nuclear extract), and
bound to DNA (DNA-binding) were analyzed by Western blotting. TBP
was used as a nuclear marker. The arrowhead in (C) indicates p50. Data
are representative of three independent experiments.
doi:10.1371/journal.pone.0034693.g004
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Several studies have reported that PD-related genes regulate glial
function. Mitochondrial damage is detected in astrocytes,
microglia, and oligodendrocytes in the SN of parkin (Park2)
knockout (KO) mice and mutant a-synuclein-expressing mice [39].
Astrocytes prepared from DJ-1 (Park7) KO mice produce higher
levels of inflammatory mediators in response to LPS than
astrocytes prepared from control mice [40]. Mixed glial prepara-
tions from parkin KO mice are more susceptible to 1-methyl-4-
phenylpyridine (MPTP)- and epoxomicin-induced cell death
compared to mixed glia from wild-type mice [41,42]. The results
of the current study add to these observations, providing evidence
that abnormalities of LRRK2 alter inflammation, which are
considered risk factors for PD.
MAPK subtypes p38, JNK, and ERK are important signaling
molecules that mediate microglial inflammatory activation in-
duced by several stimulators, including LPS, gangliosides, and
thrombin [31–33]. We found that p38 and JNK, but not ERK,
appeared to be linked to LRRK2 in LPS signaling. In Lrrk2-KD
microglia, p38 activation decreased whereas JNK and ERK were
unaffected (Fig. 2). And in TCM-HEK cells, overexpression of
LRRK2-WT and various LRRK2 mutants altered the phosphor-
ylation levels of JNK and p38 (Fig. 5). LRRK2 was previously
reported to phosphorylate MKK3/6 and MKK7, upstream
kinases of p38 and JNK, in HEK293T cells [43,44]. Unexpect-
edly, however, basal and LPS-induced MKK3/6 phosphorylation
levels were not changed in Lrrk2-KD microglia and hLRRK2-
overexpressing TCM-HEK cells compared to that in parental cells
(Figs. 2D, 2E and 5D). Therefore, LRRK2 may regulate p38
through MKK-independent pathway(s) in microglia and TCM-
HEK cells. Accordingly, in the immune system, TAK1-binding
protein 1 (TAB1) has been suggested as a new upstream regulator
Figure 5. Effect of hLRRK2 overexpression on p38 and JNK phosphorylation in HEK293T cells. (A) LPS-responsive HEK293T cells (TCM-
HEK), prepared as described in Materials and Methods, were co-transfected with empty pcDNA3.1 for the following control experiments. LPS (100 ng/
mL) induced phosphorylation of p38, and JNK was as analyzed by Western blotting. (B, D) TCM-HEK cells co-transfected with c-myc-tagged hLRRK2
(WT, G2019S [2019], D1994A [1994], and G2385R [2385]) were treated with LPS (100 ng/mL) for the indicated times. Empty vector (mock) was used as
a control. c-myc and a-tubulin were used as markers of LRRK2 expression and loading controls, respectively. Phosphorylation levels of p38, JNK, and
MKK3/6 were analyzed by Western blotting. Phosphorylation of JNK was indicated with arrowhead. (C) Band intensities in (B) were quantified using a
densitometer. Values are means 6 SEMs of three independent experiments (+p=0.054, *p,0.05, **p,0.01 vs. mock in LPS-untreated group [2LPS];
#p,0.05; ##p,0.01 vs. mock in LPS-treated group [+LPS]; ns, not significant). Data are representative of three independent experiments.
doi:10.1371/journal.pone.0034693.g005
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cellular characteristics of HEK293T cells. Thus LRRK2 overex-
pression may activate p38 MAPK through MKK3/6-independent
pathway(s) in TCM-HEK.
Although ERK activation is involved in LRRK2-G2019S-
induced cell death and neurite shortening [23,46,47], it was
difficult to reach a conclusion about the effect of LRRK2
overexpression on ERK activation in TCM-HEK cells, because
LPS barely activated ERK and the basal levels of ERK activation
exhibited too much variation between experiments. The enhanced
kinase activity of G2019S, which is the most prominent LRRK2
mutant found in PD patients, has been suggested to be crucial for
Figure 6. Effect of hLRRK2 overexpression on the NF-kB signaling pathway and NF-kB activity in HEK293T cells. (A) HEK293T cells
(parental or TCM-HEK) were transfected with a 56NF-kB–luciferase reporter construct, empty vector (mock), or hLRRK2 expression vector. One unit is
the basal NF-kB activity detected in untreated parental HEK293T cells. Left: NF-kB activity was measured by luciferase assay. Right: LRRK2 expression
was confirmed by Western blotting for c-myc. b-actin was used as a loading control. Values are means 6 SEMs of three independent experiments.
(**p,0.01 vs. mock). (B) LPS induced a dose-dependent increase in NF-kB activity in TCM-HEK cells with or without LRRK2. Cells were treated with the
indicated amount of LPS for 6 h. The values shown are fold-induction relative to the values of NF-kB activity in unstimulated TCM-HEK cells,
expressed as means 6 SEMs of three independent experiments (*p,0.05, **p,0.01 vs. mock). (C) Upper panel: TCM-HEK cells were transfected with
LRRK2-WT and each LRRK2 mutant, and NF-kB activity was analyzed after treating with LPS (10 ng/mL) for 6 h. Lower panel: Expression of LRRK2
mutants was detected by Western blotting. Values are means 6 SEMs of three independent experiments. (D) TCM-HEK cells were transfected with
mock, G2019S (100, 250 and 750 ng), and G2385R (100 and 500 ng) hLRRK2 expression vector. Values are means 6 SEMs of three independent
experiments. Upper panel: NF-kB activity measured by luciferase assay. Lower panel: LRRK2 levels determined by Western blotting (*p,0.05; ns, not
significant). (E) NF-kB DNA-binding activity was analyzed by EMSA. Nuclear extracts were obtained from mock and LRRK2-WT-overexpressing TCM-
HEK cells stimulated with LPS (10 ng/mL) for the indicated times. (F) A supershift assay was performed using nuclear extracts obtained 1 h after LPS
treatments and preincubated with NF-kB p50 and p65 antibodies. Arrowheads indicate p50/p65 complex. Specific binding (arrowhead) was analyzed
using an excess (206) of unlabeled (Cold) DNA.
doi:10.1371/journal.pone.0034693.g006
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kinase activity of LRRK2 is linked to the regulation of
inflammatory responses is questionable. TCM-HEK cells that
expressed LRRK2-WT and/or LRRK2-G2019S similarly en-
hanced both basal and LPS-induced phosphorylation of p38 and
JNK (Fig. 5B, 5C), whereas only basal p38 activity was increased
in cells that expressed LRRK2-D1994A (a kinase dead mutant),
and these cells lost the ability to react to LPS (Fig. 5B, 5C).
Therefore, the kinase activity of LRRK2 appeared to be important
for enhancing LPS-induced inflammatory responses. The WD-
domain mutant, LRRK2-G2385R, similar to LRRK2-D1994A,
regulated p38 and JNK activation in the absence and presence of
LPS, although the kinase activity of LRRK2-G2385R was not
directly analyzed. Additionally, we found that IFN-c-induced
iNOS expression and NO production were significantly reduced in
Lrrk2-KD microglia (Figure S2A, S2B). Furthermore, IFN-c-
induced phosphorylation of p38 and JNK but not phosphorylation
of STAT-1 was reduced in Lrrk2-KD microglia (Figure S2C,
S2D). In agreement with our results, leukocytes and PMBCs
isolated from PD patients carrying the LRRK2-G2019S mutant
exhibited differential expression and activation of p38 and JNK,
but not ERK, compared to healthy controls [19,48].
Activation of the transcription factor NF-kB is essential for the
expression of inflammatory mediators in microglia [32–34]. We
observed that LPS-induced transcriptional activity of NF-kB was
significantly inhibited in Lrrk2-KD microglia (Fig. 3A). However,
the mechanisms underlying LRRK2 regulation of NF-kB
transcriptional activity may not be simple. Several studies have
reported that p38 MAPK enhances NF-kB transcriptional activity
[49–51]. Accordingly, we examined whether decreased NF-kB
transcriptional activity in Lrrk2-KD cells was related to decreased
p38 MAPK activity. However, both pharmacological inhibition of
p38 with SB203580 and siRNA-mediated p38 knockdown
enhanced rather than inhibited NF-kB luciferase activity in
microglia (data not shown), suggesting that Lrrk2 affects NF-kB
transcriptional activity independently of p38 MAPK. Neither
degradation of IkB nor nuclear translocation of NF-kB proteins,
p65 and p50, were different between control and Lrrk2-KD
microglia (Figs. 3B, 4C). However, EMSA supershift assays and
DNA affinity precipitation experiments showed that Lrrk2
regulated NF-kB-DNA complex formation; particularly, the
amount of p50/p50 homodimer-DNA complexes, which have
been suggested to act as an inhibitory transcription factor, was
increased in Lrrk2-KD microglia compared to control cells
(Fig. 4A–C). As an effort to reveal how p50/p50 homodimer-
DNA complexes increased in Lrrk2-KD cells, we examined
phosphorylation of serine 337 (p-Ser337) of p50, which is
important for DNA binding of p50/p50 homodimer [52].
However, the p-Ser337 levels were not altered in Lrrk2-KD cells
with or without LPS treatment (data not shown). We also
examined phosphorylation of serine 276 (p-Ser276), and serine
536 (p-Ser536) of p65 since posttranslational modification of p65 is
important for NF-kB transcriptional activity independently of NF-
kB subunit dimerization and/or IkB-mediated nuclear transloca-
tion [53–55]. However, we found no significant changes in p-
Ser276 or p-Ser536 levels of p65 in Lrrk2-KD microglia (data not
shown). Therefore, additional studies are required to reveal how
LRRK2 regulates NF-kB activity.
Increasing attention has gradually focused on the importance of
neuroinflammation as a risk factor in the pathogenesis of PD
[12,13]. For example, genetic variations in the inflammation-
regulatory gene, HLA, were found to be associated with late-onset,
sporadic PD [56], which is in an accord with previous finding that
HLA-DR-positive microglia are commonly found in the SN of PD
patients [57]. Although PD mouse models carrying hLRRK2
pathogenic mutants fail to develop nigrostriatal neurodegeneration
despite the presence of age-dependent motor deficits [7–10],
animal models in which viruses carrying hLRRK2 pathogenic
mutants are directly injected into the striatum do develop nigral
neurodegeneration of infected neurons [58,59]. Direct injection of
virus could induce inflammatory responses, which cooperate with
pathogenic LRRK2 to develop nigrostriatal neurodegeneration.
Previous reports have shown that persistent systemic inflammation
induces the loss of dopaminergic neurons in parkin-deficient mice
[60], supporting the hypothesis that inflammation enhances the
toxicity of genetic factors and/or environmental toxins. In
addition, central and systemic IL-1 expression in an animal model
was shown to enhance 6-hydroxydopamine-mediated neurode-
generation in the SN [61].
The results of this study indicate that LRRK2 is a positive
regulator of brain inflammation. Therefore, in injury states in
which inflammation occur, LRRK2 abnormally regulates brain
inflammation, which could cooperate with neuronal defects
produced by abnormal LRRK2 and further increase the risk of
developing PD.
Supporting Information
Figure S1 LRRK loss-of-function mutant express low
levels of antimicrobial proteins (AMP) genes. Wild type
(w
1118) and LRRK loss-of-function mutant (LRRK
P1) fly were a
gift from Dr. Chung in Seoul National University, Korea [30]. (A)
Expression levels of drosophila Rpl32, attacin A, diptericin and LRRK
were analyzed by conventional RT-PCR. The following primers
were used for amplification of the target genes: Rpl32,5 9-
AGATCGTGAAGAAGCGCACCAAG-39 (sense) and 59-CAC-
CAGGAACTTCTTGAATCCGG-39 (antisense); Attcin A,5 9-A-
CAAGCATCCT AATCGTGGC-39 (sense) and 59-TCAGATC-
CAAACGAGCATCAG-39 (antisense); Diptericin,5 9-TTTGGC-
TTATCCGATGCCCG-39 (sense) and 59-ATGGTCCTCCCA-
AGTGCTGT-3 (antisense); LRRK,5 9-GTGGCTGTCGGAA-
CGCATAAC-39 (sense) and 59-GCCGCACCACAATTCATA-
G-39 (antisense). (B) mRNA levels of AMPs, attacin A and
diptericin, were quantified by qRT-PCR at 5 or 30 day after
eclosion. mRNA was prepared from a total of 25–30 flies. The
mRNA level of Rpl32 was used as an internal control. Values are
means 6 SEM of three independent experiments (**p,0.01 vs.
control fly).
(TIF)
Figure S2 IFN-c-induced inflammatory responses are
attenuated in Lrrk2-KD microglia. Control (Con) and
Lrrk2-KD (KD) cells were treated with 10 ng/ml mouse IFN-c
for the indicated times (A, C, D) and 48 h (B). (A, C, D) Levels of
iNOS protein (A), phospho-STAT1 (Tyr701) (C) and phospho-p38
and –JNK (D) were analyzed by Western blotting. a-tubulin was
used as an internal control. Data are representative of three
independent experiments. (B) The amount of nitrite converted
from NO in the media was measured using Griess reagent as
described in methods. Values are means 6 SEM of three samples.
*, p,0.05 vs. control.
(TIF)
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